In human AML cells, ABD957 blocks N-Ras depalmitoylation with higher proteome selectivity than Palm M. ABD957 synergizes with MEK inhibitors to suppress N-Ras signaling and inhibit NRAS-mutant AML growth, suggesting ABHD17 inhibitors as targeted therapies for NRAS-driven cancers (215). Here, NRAS is linked to acute myeloid leukemia.